PDF(Pubmed)
Abstract：
BACKGROUND: Neuromuscular diseases (NMD) emerged as one of the main side effects of the COVID-19 vaccination. We pooled and summarized the evidence on the clinical features and outcomes of NMD associated with COVID-19 vaccination.
METHODS: We comprehensively searched three databases, Medline, Embase, and Scopus, using the key terms covering \"Neuromuscular disease\" AND \"COVID-19 vaccine\", and pooled the individual patient data extracted from the included studies.
RESULTS: A total of 258 NMD cases following COVID-19 have been reported globally, of which 171 cases were Guillain-Barré syndrome (GBS), 40 Parsonage-Turner syndrome (PTS), 22 Myasthenia Gravis (MG), 19 facial nerve palsy (FNP), 5 single fiber neuropathy, and 1 Tolosa-Hunt syndrome. All (100%) SFN patients and 58% of FNP patients were female; in the remaining NMDs, patients were predominantly male, including MG (82%), GBS (63%), and PTS (62.5%). The median time from vaccine to symptom was less than 2 weeks in all groups. Symptoms mainly appeared following the first dose of vector vaccine, but there was no specific pattern for mRNA-based.
CONCLUSIONS: COVID-19 vaccines might induce some NMDs, mainly in adults. The age distribution and gender characteristics of affected patients may differ based on the NMD type. About two-thirds of the cases probably occur less than 2 weeks after vaccination.
METHODS: We comprehensively searched three databases, Medline, Embase, and Scopus, using the key terms covering \"Neuromuscular disease\" AND \"COVID-19 vaccine\", and pooled the individual patient data extracted from the included studies.
RESULTS: A total of 258 NMD cases following COVID-19 have been reported globally, of which 171 cases were Guillain-Barré syndrome (GBS), 40 Parsonage-Turner syndrome (PTS), 22 Myasthenia Gravis (MG), 19 facial nerve palsy (FNP), 5 single fiber neuropathy, and 1 Tolosa-Hunt syndrome. All (100%) SFN patients and 58% of FNP patients were female; in the remaining NMDs, patients were predominantly male, including MG (82%), GBS (63%), and PTS (62.5%). The median time from vaccine to symptom was less than 2 weeks in all groups. Symptoms mainly appeared following the first dose of vector vaccine, but there was no specific pattern for mRNA-based.
CONCLUSIONS: COVID-19 vaccines might induce some NMDs, mainly in adults. The age distribution and gender characteristics of affected patients may differ based on the NMD type. About two-thirds of the cases probably occur less than 2 weeks after vaccination.
摘要：
背景：神经肌肉疾病（NMD）是COVID-19疫苗接种的主要副作用之一。我们汇集并总结了与COVID-19疫苗接种相关的NMD临床特征和结局的证据。
方法：我们全面搜索了三个数据库，Medline,Embase,还有Scopus,使用涵盖“神经肌肉疾病”和“COVID-19疫苗”的关键术语，并汇总从纳入研究中提取的个体患者数据。
结果：全球共报告了258例新冠肺炎后NMD病例，其中171例为格林-巴利综合征（GBS），40牧师-特纳综合征（PTS），22重症肌无力（MG），19面神经麻痹（FNP），5单纤维神经病变，和1Tolosa-Hunt综合征.所有（100％）SFN患者和58％的FNP患者均为女性；在其余的NMD中，患者主要为男性，包括MG（82%），GBS（63%），和PTS(62.5%)。所有组从疫苗到症状的中位时间小于2周。症状主要出现在第一剂载体疫苗后，但是没有基于mRNA的特定模式。
结论：COVID-19疫苗可能会诱导一些NMD，主要是成年人。受影响患者的年龄分布和性别特征可能因NMD类型而异。大约三分之二的病例可能发生在疫苗接种后不到2周。
方法：我们全面搜索了三个数据库，Medline,Embase,还有Scopus,使用涵盖“神经肌肉疾病”和“COVID-19疫苗”的关键术语，并汇总从纳入研究中提取的个体患者数据。
结果：全球共报告了258例新冠肺炎后NMD病例，其中171例为格林-巴利综合征（GBS），40牧师-特纳综合征（PTS），22重症肌无力（MG），19面神经麻痹（FNP），5单纤维神经病变，和1Tolosa-Hunt综合征.所有（100％）SFN患者和58％的FNP患者均为女性；在其余的NMD中，患者主要为男性，包括MG（82%），GBS（63%），和PTS(62.5%)。所有组从疫苗到症状的中位时间小于2周。症状主要出现在第一剂载体疫苗后，但是没有基于mRNA的特定模式。
结论：COVID-19疫苗可能会诱导一些NMD，主要是成年人。受影响患者的年龄分布和性别特征可能因NMD类型而异。大约三分之二的病例可能发生在疫苗接种后不到2周。
